A new era in anticancer peptide vaccines (Q37699160)

22 August 2017

1 reference

title

A new era in anticancer peptide vaccines (English)

1 reference

22 August 2017

Sonia A Perez

1

1 reference

22 August 2017

Eric von Hofe

2

1 reference

22 August 2017

Nikoletta L Kallinteris

3

1 reference

22 August 2017

Angelos D Gritzapis

4

1 reference

22 August 2017

George E Peoples

5

1 reference

22 August 2017

Michael Papamichail

6

1 reference

22 August 2017

Constantin N Baxevanis

7

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 May 2010

1 reference

22 August 2017

1 reference

22 August 2017

116

1 reference

22 August 2017

9

1 reference

22 August 2017

2071-2080

1 reference

Helper T cell determinant peptide contributes to induction of cellular immune responses by peptide vaccines against hepatitis C virus

22 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

The frequency of high avidity T cells determines the hierarchy of determinant spreading

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

7 January 2021

Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

7 January 2021

Immunological aspects of cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

7 January 2021

Next generation of immunotherapy for melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

7 January 2021

A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

7 January 2021

Combination of chemotherapy and immunotherapy for cancer: a paradigm revisited

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

7 January 2021

Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

7 January 2021

Combined modality immunotherapy and chemotherapy: a new perspective

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

7 January 2021

Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

7 January 2021

A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

7 January 2021

Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

7 January 2021

The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

7 January 2021

Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

7 January 2021

A mouse mutant p53 product recognized by CD4+ and CD8+ T cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

7 January 2021

Induction of Tumor-Specific CD4+ and CD8+ T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

7 January 2021

Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

7 January 2021

Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

7 January 2021

Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

7 January 2021

Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

7 January 2021

Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

7 January 2021

Serum proteases alter the antigenicity of peptides presented by class I major histocompatibility complex molecules

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

7 January 2021

Help for cytotoxic-T-cell responses is mediated by CD40 signalling.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

7 January 2021

T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

7 January 2021

Rational Peptide-based vaccine design for cancer immunotherapeutic applications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

7 January 2021

IFN inducibility of major histocompatibility antigens in tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

7 January 2021

HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

7 January 2021

Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

7 January 2021

The CD8+ T cell repertoire against Her-2/neu antigens in neu transgenic mice is of low avidity with antitumor activity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

7 January 2021

T helper epitopes enhance the cytotoxic response of mice immunized with MHC class I-restricted malaria peptides.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

7 January 2021

Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

7 January 2021

Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

7 January 2021

Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

7 January 2021

HER-2/neu-derived peptide 884-899 is expressed by human breast, colorectal and pancreatic adenocarcinomas and is recognized by in-vitro-induced specific CD4(+) T cell clones

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

7 January 2021

Peptide HER2(776-788) represents a naturally processed broad MHC class II-restricted T cell epitope

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

7 January 2021

Induction of potent CD4+ T cell-mediated antitumor responses by a helper HER-2/neu peptide linked to the Ii-Key moiety of the invariant chain

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

7 January 2021

Ii-Key/HER-2/neu(776-790) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

7 January 2021

Ii-Key/MHC class II epitope hybrids: a strategy that enhances MHC class II epitope loading to create more potent peptide vaccines.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

7 January 2021

Increasing the potency of MHC class II-presented epitopes by linkage to Ii-Key peptide

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

7 January 2021

Linkage of Ii-Key segment to gp100(46-58) epitope enhances the production of epitope-specific antibodies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

7 January 2021

Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

7 January 2021

CD4+ T cells in antitumor immunity: utility of an li-key HER2/neu hybrid peptide vaccine (AE37)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

7 January 2021

Harnessing the immune system to treat cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

7 January 2021

Breast cancer vaccines: promise for the future or pipe dream?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

7 January 2021

Vaccination for treatment and prevention of cancer in animal models.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

7 January 2021

Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

7 January 2021

Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

7 January 2021

Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835].

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

7 January 2021

Targeting cancer stem cells for more effective therapies: Taking out cancer's locomotive engine.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

7 January 2021

Applying the principles of stem-cell biology to cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

7 January 2021

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

7 January 2021

The immunogenicity of human embryonic stem-derived cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

7 January 2021

Melanoma stem cells: targets for successful therapy?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

7 January 2021

Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

7 January 2021

Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

7 January 2021

Breast cancer cells expressing stem cell markers CD44+ CD24 lo are eliminated by Numb-1 peptide-activated T cells.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24988

7 January 2021

Identifiers

DOI

10.1002/CNCR.24988

1 reference

22 August 2017

1 reference